Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCST 905 is a potent and selective BRAFV600E Degrader (PROTAC®) (DC50 = 18 nM). CST 905 comprises a ligand for the von Hippel Lindau (VHL) E3 ligase joined by a linker to a PLX-derived ligand. Unlike other BRAFV600E Degraders, CST 905 does not activate ERK.
B-Raf antibody validated for Simple Western™ (automated Western) instruments and Western Blot also available: Catalog # AF3424.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
M. Wt | 1025.2 |
Formula | C51H58F2N10O7S2 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
InChI Key | VOFGLMSAVUMRLF-FGUOTCRGSA-N |
Smiles | FC1=C(C(F)=CC=C1NS(N(C)CC)(=O)=O)C(C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)N5CCN(CC5)CC(N[C@H](C(N6[C@@H](C[C@H](C6)O)C(NCC7=CC=C(C=C7)C8=C(N=CS8)C)=O)=O)C(C)(C)C)=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 102.52 | 100 |
The following data is based on the product molecular weight 1025.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 0.98 mL | 4.88 mL | 9.75 mL |
5 mM | 0.2 mL | 0.98 mL | 1.95 mL |
10 mM | 0.1 mL | 0.49 mL | 0.98 mL |
50 mM | 0.02 mL | 0.1 mL | 0.2 mL |
References are publications that support the biological activity of the product.
Miller et al (2022) Encoding BRAF inhibitor functions in protein degraders. RSC Med.Chem. 13 731 PMID: 35814929
If you know of a relevant reference for CST 905, please let us know.
Keywords: CST 905, CST 905 supplier, CST905, degraders, degradation, targeted, protein, degrader, E3, ligase, protac, BRAF, V600E, BRAFV600E, potent, selective, VHL, von, hippel, lindau, PLX, ERK, Raf, Kinase, and, Ras, Degraders, 7745, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for CST 905. Do you know of a great paper that uses CST 905 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review CST 905 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia